logo

Last Update

This profile was last updated on 12/5/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong William Macias?

William L. Macias

Senior Medical Director

Eli Lilly and Company

Direct Phone: (317) ***-****direct phone

Email: w***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Eli Lilly and Company

10300 Campus Point Dr.

San Diego, California,92121

United States

Company Description

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true ...more

Web References(26 Total References)


CRRT - Faculty

www.crrtonline.com [cached]

William Macias, MD, PhD
Lilly Research Laboratories Eli Lilly and Company


CRRT - Faculty

www.crrtonline.com [cached]

William Macias, MD, PhD
William Macias, MD, PhD Lilly Research Laboratories Eli Lilly and Company Dr. William Macias is Senior Medical Director for the cardiovascular and acute care platform team at Eli Lilly and Company. In his role, Dr. Macias has worldwide responsibility for the clinical development of multiple compounds in cardiovascular and critical care medicine. Most recently, he oversaw the late phase clinical development, submission and registration of Xigris for the treatment of patients with severe sepsis. Since 1996, Dr. Macias has been involved in the design and conduct of Phase IIa, Phase IIb, Phase III and Phase IV studies of multiple compounds for the treatment of severe sepsis and acute coronary syndromes. Prior to joining Lilly, Dr. Macias was an Associate Professor of Medicine at Indiana University School of Medicine, Indianapolis, Indiana. As a board certified intensivist and nephrologist, he was medical director for the renal intensive care and acute dialysis units at Indiana University Hospital and fellowship director for the nephrology fellowship program. He received his fellowship training and residency training in Internal Medicine at Indiana University. He received the PhD degree in physiology in 1991 and the MD degree in 1983, both from Indiana University School of Medicine.


www.biospace.com

"This is the first phase 3 study showing that a once-daily, oral treatment significantly improved clinical outcomes compared with injectable adalimumab for patients with active RA who were also receiving treatment with methotrexate," said William Macias, M.D., Ph.D., distinguished medical fellow and global brand development leader, Lilly Bio-Medicines.


CRRT - Faculty

www.crrtonline.com [cached]

William Macias, MD, PhD
CRRT - Faculty William Macias, MD, PhD Lilly Research Laboratories Eli Lilly and Company Dr. William Macias is Senior Medical Director for the cardiovascular and acute care platform team at Eli Lilly and Company. In his role, Dr. Macias has worldwide responsibility for the clinical development of multiple compounds in cardiovascular and critical care medicine. Most recently, he oversaw the late phase clinical development, submission and registration of Xigris for the treatment of patients with severe sepsis. Since 1996, Dr. Macias has been involved in the design and conduct of Phase IIa, Phase IIb, Phase III and Phase IV studies of multiple compounds for the treatment of severe sepsis and acute coronary syndromes. Prior to joining Lilly, Dr. Macias was an Associate Professor of Medicine at Indiana University School of Medicine, Indianapolis, Indiana. As a board certified intensivist and nephrologist, he was medical director for the renal intensive care and acute dialysis units at Indiana University Hospital and fellowship director for the nephrology fellowship program. He received his fellowship training and residency training in Internal Medicine at Indiana University. He received the PhD degree in physiology in 1991 and the MD degree in 1983, both from Indiana University School of Medicine.


www.tctmd.com

"We've had a lot of discussion with FDA on this," said William Macias, MD, PhD, senior medical director at Eli Lilly and Company.
Dr. Macias argued that the increase in cancer diagnoses (94 in the prasugrel group, compared with 80 in the clopidogrel patients) was a spurious finding, and that new cell culture and animal studies show that the drug is not a tumor promoter.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory